Company intelligence / Profile preview
Neurodyn Life Sciences Inc.
Vancouver, British Columbia, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
Pre-clinical development of Progranulin/Granulin programs for ALS (first indication) with neuroprotective effects demonstrated in models of TDP-43 pathology; previously developed galantamine prodrug (GLN-1062/Alpha-1062) approved for Alzheimer's via spin-out company Alpha Cognition Inc.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculeProteinNatural product
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Alpha Cognition Inc. (spin-out for GLN-1062)LifeSci Brands Inc. (co-founded for natural products marketing)
Beyond the preview
Go deeper on Neurodyn Life Sciences Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurodyn Life Sciences Inc..